Phospho-Cyclin D1 (Thr286)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 3124R
英文名称Phospho-Cyclin D1 (Thr286)
中文名称磷酸化cyclin D1抗体
别 名Cyclin D1 (phospho T286); p-Cyclin D1 (phospho T286); AI327039; B cell ccl/lymphoma 1; B cell leukemia 1; B-cell CLL/lymphoma 1; B-cell leukemia 1; B-cell lymphoma 1 protein; BCL-1; BCL1; BCL1 oncogene; CCND 1; CCND1; CCND1 protein; CCND1/FSTL3 fusion gene, included; CCND1/IGHG1 fusion gene; CCND1/IGHG1 fusion gene, included; CCND1/IGLC1 fusion gene, included; CCND1/PTH fusion gene, included; cD1; Cyclin D1; Cyl-1; D11S287E; G1/S specific cyclin D1; MGC137744; Parathyroid adenomatosis 1; PRAD1; PRAD1 oncogene; U21B31; CCND1_HUMAN.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 细胞生物 表观遗传学
抗体来源Rabbit
克隆类型Polyclonal
Phospho-Cyclin D1 (Thr286)抗体交叉反应 Human, Mouse, Dog, Cow, Sheep,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量34kDa
细胞定位细胞核 细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human Cyclin D1 around the phosphorylation site of Thr286:AC(p-T)PT
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-Cyclin D1 (Thr286)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. [provided by RefSeq, Jul 2008].
Function:
Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma (RB)protein family including RB1 and regulates the cell-cycle duringG(1)/S transition. Phosphorylation of RB1 allows dissociation ofthe transcription factor E2F from the RB/E2F complex and thesubsequent transcription of E2F target genes which are responsiblefor the progression through the G(1) phase. Hypophosphorylates RB1in early G(1) phase. Cyclin D-CDK4 complexes are major integratorsof various mitogenenic and antimitogenic signals. Also substratefor SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent mannerand repressing its transcriptional activity. Component of theternary complex, cyclin D1/CDK4/CDKN1B, required for nucleartranslocation and activity of the cyclin D-CDK4 complex.
Subunit:
Interacts with FBXO4. Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation and modulationof CDK4-mediated kinase activity. Interacts directly with CDKN1B.Interacts with UHRF2; the interaction ubiquitinates CCND1 andappears to occur independently of phosphorylation. Can form similarcomplexes with either CDKN1A or CDKN2A. Interacts with USP2.
Subcellular Location:
Nucleus. Cytoplasm. Membrane. Note=CyclinD-CDK4 complexes accumulate at the nuclear membrane and are thentranslocated to the nucleus through interaction with KIP/CIP familymembers.
Post-translational modifications:
Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.
Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF(SKP1-cullin-F-box) protein ligase complex containing FBXO31.SCF-type ubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization.
DISEASE:
Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulingene regions. Activation of CCND1 may be oncogenic by directlyaltering progression through the cell cycle.
Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15) withthe parathyroid hormone (PTH) enhancer.
Defects in CCND1 are a cause of multiple myeloma (MM)[MIM:254500]. MM is a malignant tumor of plasma cells usuallyarising in the bone marrow and characterized by diffuse involvementof the skeletal system, hyperglobulinemia, Bence-Jones proteinuriaand anemia. Complications of multiple myeloma are bone pain,hypercalcemia, renal failure and spinal cord compression. Theaberrant antibodies that are produced lead to impaired humoralimmunity and patients have a high prevalence of infection.Amyloidosis may develop in some patients. Multiple myeloma is partof a spectrum of diseases ranging from monoclonal gammopathy ofunknown significance (MGUS) to plasma cell leukemia. Note=Achromosomal aberration involving CCND1 is found in multiplemyeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
Similarity:
Belongs to the cyclin family. Cyclin D subfamily.
SWISS:
P24385
Gene ID:
595
Phospho-Cyclin D1 (Thr286)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-Cyclin D1 (Thr286)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 NECAB1 神经元钙结合相关蛋白EFCBP1抗体
合格 Creatine kinase B type 脑肌酸激酶BCK抗体
合格 HLA-DR/HLA DRB1 HLA-DR抗体
合格 PPP2R5C 蛋白质磷酸酶2调节亚基5C/PP2A-B56-γ抗体
合格 PPP2R5D 蛋白质磷酸酶2调节亚基5D/PP2A-B56-δ抗体
合格 Phosphoserine/threonine 磷酸化丝氨酸/苏氨酸抗体
合格 CHRM4 毒蕈碱型乙酰胆碱受体M4抗体
合格 PAX1 配对盒基因1抗体
合格 phospho-SAPK3 (Thr183+Tyr185) 磷酸化丝裂原活化蛋白激酶磷酸酶p38γ抗体
合格 GLUR4 离子型谷氨酸受体4抗体
合格 Omgp 少突细胞髓磷脂糖蛋白抗体
合格 MGLUR3 代谢型谷氨酸受体-3抗体
合格 MGLUR1 + MGLUR5 促代谢型谷氨酸受体1+5抗体
合格 GPR18 G蛋白偶联受体18抗体
合格 GPR1 G蛋白偶联受体1抗体
合格 合格 PAX8 配对盒基因8抗体
合格 GPR125 G蛋白偶联受体125抗体
合格 GPR136 G蛋白偶联受体136抗体
合格 GPR126 G蛋白偶联受体126抗体
合格 GPRC5B G蛋白偶联受体C5B抗体
合格 TRADD 肿瘤坏死因子受体1相关死亡域蛋白抗体
合格 GRASP 一般受体磷酸肌醇相关支架蛋白1抗体
合格 GODZ 棕榈酰转移酶GODZ抗体
合格 Paralemmin 1 细胞膜调控蛋白Paralemmin 1抗体
合格 合格 CLIC6 氯离子通道蛋白6抗体
合格 TOP2A DNA拓普西异构酶Ⅱ抗体
合格 ADRA2C α2C-AR肾上腺素能受体抗体
合格 合格 5HT1F Receptor 5-羟色胺受体1F抗体
合格 5HT2A Receptor 5-羟色胺受体2A抗体
合格 合格 5HT2B Receptor 5-羟色胺受体2B抗体
合格 5HT7 Receptor 5-羟色胺受体7抗体
合格 合格 ROCK2 Rho相关蛋白激酶2抗体
合格 合格 合格 GABRA2 G氨基丁酸A型受体α2/GABAA Rα2抗体
合格 GABRB2 G氨基丁酸受体β2/GABAA Rβ2抗体
合格 TLX2 T**细胞白血病同源蛋白2抗体
合格 合格 合格 GLI1 脑胶质瘤相关蛋白抗体（锌指蛋白5）